{"title": "Janssen's newly merged infectious disease and vaccine unit sees significant pipeline cuts", "author": "Max Bayer", "url": "https://www.fiercebiotech.com/biotech/janssens-newly-merged-infectious-disease-and-vaccine-unit-sees-significant-pipeline-cuts", "hostname": "fiercebiotech.com", "description": "It's been six months since Johnson & Johnson's overhaul of its infectious disease and vaccine units went into effect, and it appears that cuts to the portfolio have yet to stop. | Johnson & Johnson's reassessment of its infectious disease and vaccine work does not appear to be over, with the company cutting the number of assets in development in half. The cuts come six months after the overhaul of the two units was first disclosed to staff.", "sitename": "FierceBiotech", "date": "2023-07-20", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Fierce 50 Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Subscribe Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Fierce 50 Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}